DexCom Builds a Back Door While It Waits for Medicare
A lost PBM contract, a patient-navigation service built for a reimbursement decision that has not happened yet, and a management team insisting nothing has changed
DXCM · Earnings Call · 2026-10-29
DexCom Builds a Back Door While It Waits for Medicare
For eight quarters, DexCom's investment case has rested on a single sentence: Medicare coverage for type 2 non-insulin users is a matter of when, not if. That sentence was still true on Thursday. It was also, for the first time, no longer the most interesting thing on the call.
The beat, and the crack at the end of it
Third-quarter revenue of $1.34 billion grew 11% on both a reported and organic basis, U.S. revenue rose 14%, and gross margin jumped roughly 380 basis points to 65.1%. Operating margin reached 25.3%, up from 22.6%. Management raised full-year revenue guidance to $5.20–$5.25 billion (12–13% growth), lifted operating margin guidance to approximately 24% and EBITDA to roughly 32%, and noted it had already generated over $900 million of free cash flow through three quarters — enough to complete a $1 billion buyback and authorize another.
That revenue base has grown from $742 million in the first quarter of 2023 to $1.31 billion by the June quarter, and gross margin, which bottomed near 60% in 2024 on scrap and freight problems, has clawed back to 63.4% in the June quarter with another step up since. Then the crack: the raised guide implies midpoint fourth-quarter growth of just 10%, a deceleration from the 11% just printed. That is the price of lapping a soft international comparison and absorbing a new factory.
A contract the company says does not matter, described in language that says it does
The question analysts actually wanted answered was about a lost PBM contract. Management's response was a masterclass in sizing something small while describing something large. The PBM, Jereme Sylvain said, “represents less than 4% of our U.S. revenue results” — Jereme Sylvain, Chief Operating Officer and Chief Financial Officer · 2026-10-29 — and therefore the 2027 financial impact should be modest, because patients who move off preferred status pay a much steeper price. Pressed on the magnitude, he did not soften it: “It is not like a 5% increase. It is much higher than that.” — Jereme Sylvain, Chief Operating Officer and Chief Financial Officer · 2026-10-29
That is the whole trade. Lose some patients, keep the ones who will pay, and collect a better net price on the remainder. It is a coherent strategy — and it is also the most explicit admission in years that DexCom's pricing power, not its category growth, is what defends the income statement when a payer flips.
If you see that individual try to switch to a competitor, it is not compatible with their insulin pump. There's multiple pumps out there that competitors are not compatible with here in the U.S. … I think trying to consider that as a comparable product is not even in the realm of reality.
That is Jake Leach arguing that formulary decisions are being made on a false equivalence between CGM systems. The reframing matters: the company has moved from lobbying for coverage expansion to litigating the terms of equal access inside formularies that already exist.
DexCom Direct: a Medicare product that arrived early
The genuinely new thing on this call was not a sensor. It was a service. Leach disclosed that DexCom Direct, a patient-navigation desk built in anticipation of Medicare expansion, will launch early next year — pulled forward to catch anyone struggling to find medical benefit coverage through a DME channel or a prior authorization. The economics are not free: “there'll be a cost underneath it to support the benefits check, the white glove service that we expect to provide for folks” — Jereme Sylvain, Chief Operating Officer and Chief Financial Officer · 2026-10-29.
Read that again. A device manufacturer is vertically integrating into insurance navigation because the pharmacy counter is now a hostile environment. This is not a new theme invented here — Alexion's call this week leaned on a site of care strategy, and Phathom spent its airtime on co pay and patient pocket cost. Across medtech, the fight has migrated from clinical differentiation to who absorbs the friction between a prescription and a filled script.
Evidence as leverage
The strongest new asset disclosed is not financial. The CONNECT data was published in the New England Journal of Medicine — the first time in roughly two decades the journal has run standalone CGM data — showing a 1.6% A1C improvement and a 0.9% gap versus control. Management expects that to shape the upcoming ADA Standards of Care update as level A evidence, which in turn is the lever they have handed to the medical directors evaluating Medicare expansion.
Timing has not changed, and that is the story. A year ago the framing was that coverage was simply a matter of time; in April, Leach said “it is really just a matter of time” — Jacob Steven Leach, President and CEO · 2026-04-30; in July he said “we do expect to hear back from CMS on that decision before the end of this year” — Jacob Steven Leach, President and CEO · 2026-07-30; this week: “We have not changed our perspective on the Medicare timing” — Jake Leach, President and Chief Executive Officer · 2026-10-29, with coverage taking effect mid-2027. The catalyst has not moved — it has been politely deferred by another four quarters while a new vocabulary of access fills the vacuum.
The thing management stopped talking about
What fell out of the conversation is instructive. The keyword metabolic health was a top-five theme for this company as recently as the first quarter and is now among the quarter's sharpest decliners; the pre-diabetes and consumer-wellness framing that once sat alongside Stelo has quietly receded behind formulary mechanics. The growth algorithm has become a coverage algorithm.
Meanwhile the pricing narrative has inverted versus the competition. Asked twice about cash-pay discounting offshore, Sylvain was flat: “We have not seen a degradation of pricing around the world” — Jereme Sylvain, Chief Operating Officer and Chief Financial Officer · 2026-10-29, adding that gross margins are the highest since the fourth quarter of 2022. Either DexCom is genuinely advantaged in the geographies where it overlaps least with a price-aggressive rival, or it is a quarter from finding out. Also underappreciated: a signed deal to acquire its largest remaining European distributor, closing next year, converting a channel into direct revenue — “It certainly is a growth lever as we move into next year” — Jake Leach, President and Chief Executive Officer · 2026-10-29.
The setup
Twelve months ago this management team pre-emptively told the Street that 2026's top end would come in below consensus. It has since raised twice. That pattern — sandbag, then deliver — is why the shares are up roughly 15% over the last ninety trading days, though still about 13% below their August peak and more than 50% below the 2021 high. The valuation reflects a business that has de-rated from a category story to a cash story: price to revenue of 5.1x, down roughly a third year over year, against 85x in late 2021, on an operating margin that has roughly doubled off its 2023 low.
The honest read: DexCom won the manufacturing war it was losing two years ago, and is now fighting a distribution and reimbursement war it did not choose. The Medicare decision remains the biggest single swing factor in the equity — but between now and mid-2027, the thing to watch is whether DexCom Direct can convert a lost formulary slot into a retained patient. That is a channel business bolted onto a sensor company, and it is the first genuinely new strategic artifact here in years.